Solvay Pharmaceuticals, Inc. announced today that Stephen Hill, B.M.,
B.Ch., M.A., F.R.C.S., president and chief executive officer, has been
named to the Board of Directors of the Pharmaceutical Research and
Manufacturers of America (PhRMA). Hill was elected to serve a three-year
term through April 2011.
PhRMA represents the country’s leading
pharmaceutical research and biotechnology companies, which are devoted
to inventing medicines that allow patients to live longer, healthier,
and more productive lives.
“I look forward to collaborating with my
colleagues on the Board of PhRMA to further the organization’s
mission, address issues facing Solvay Pharmaceuticals and the entire
industry and most importantly, help improve the lives of the patients we
serve,” said Hill.
“PhRMA looks forward to the expertise and
leadership Dr. Hill brings to the Board as we continue to advocate for
public policies that encourage the discovery of life-saving and life
enhancing new medicines for patients,” said
Billy Tauzin, president and CEO of PhRMA.
Before joining Solvay, Hill most recently served as president and CEO of
biotechnology firm ArQule, Inc. since 1999. Prior to his position at
ArQule, Hill was the Head of Global Drug Development at F. Hoffmann-La
Roche Ltd. from 1997-1999. He joined Roche in 1989 as Medical Adviser to
Roche Products in the United Kingdom and held several senior positions
there that included U.K. Medical Director and Head of International Drug
Regulatory Affairs at Roche headquarters in Basel, Switzerland. Hill is
a Fellow of the Royal College of Surgeons of England and holds his
scientific and medical degrees from St. Catherine's College at Oxford
University.
About Solvay Pharmaceuticals, Inc.
Solvay Pharmaceuticals, Inc., of Marietta, Georgia is the U.S.
subsidiary of Solvay Pharmaceuticals. For more information, visit www.solvaypharmaceuticals-us.com.
Solvay Pharmaceuticals is a research driven group of companies that
constitute the global pharmaceutical business of the Solvay Group. The
company seeks to fulfill carefully selected, unmet medical needs in the
therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines,
gastroenterology, and men’s and women’s
health. Its 2007 sales were EUR 2.6 billion and it employs more than
9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.
SOLVAY is an international chemical and pharmaceutical Group with
headquarters in Brussels. It employs more than 28,000 people in 50
countries. In 2007, its consolidated sales amounted to EUR 9.6 billion,
generated by its three sectors of activity: Chemicals, Plastics and
Pharmaceuticals. Solvay (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB -
Reuters: SOLBt.BR) is listed on the NYSE Euronext stock exchange in
Brussels. Details are available at www.solvay.com
|